0000899243-20-028807.txt : 20201020
0000899243-20-028807.hdr.sgml : 20201020
20201020200515
ACCESSION NUMBER: 0000899243-20-028807
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201016
FILED AS OF DATE: 20201020
DATE AS OF CHANGE: 20201020
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Flagship Ventures Fund V General Partner LLC
CENTRAL INDEX KEY: 0001724575
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39615
FILM NUMBER: 201249339
BUSINESS ADDRESS:
STREET 1: 55 CAMBRIDGE PARKWAY
STREET 2: SUITE 800E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-868-1888
MAIL ADDRESS:
STREET 1: 55 CAMBRIDGE PARKWAY
STREET 2: SUITE 800E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Flagship Ventures Fund V, L.P.
CENTRAL INDEX KEY: 0001627639
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39615
FILM NUMBER: 201249340
BUSINESS ADDRESS:
STREET 1: ONE MEMORIAL DRIVE, 7TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-868-1888
MAIL ADDRESS:
STREET 1: ONE MEMORIAL DRIVE, 7TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Flagship V VentureLabs Rx Fund, L.P.
CENTRAL INDEX KEY: 0001724939
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39615
FILM NUMBER: 201249341
BUSINESS ADDRESS:
STREET 1: 55 CAMBRIDGE PARKWAY
STREET 2: SUITE 800E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-868-1888
MAIL ADDRESS:
STREET 1: 55 CAMBRIDGE PARKWAY
STREET 2: SUITE 800E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: AFEYAN NOUBAR
CENTRAL INDEX KEY: 0001222012
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39615
FILM NUMBER: 201249342
MAIL ADDRESS:
STREET 1: C/O FLAGSHIP PIONEERING, INC.
STREET 2: 55 CAMBRIDGE PARKWAY, SUITE 800E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Codiak BioSciences, Inc.
CENTRAL INDEX KEY: 0001659352
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O ARCH VENTURE PARTNERS
STREET 2: 999 THIRD AVENUE, SUITE 3400
CITY: SEATTLE
STATE: WA
ZIP: 98104
BUSINESS PHONE: 857-400-4222
MAIL ADDRESS:
STREET 1: C/O ARCH VENTURE PARTNERS
STREET 2: 999 THIRD AVENUE, SUITE 3400
CITY: SEATTLE
STATE: WA
ZIP: 98104
FORMER COMPANY:
FORMER CONFORMED NAME: Codiak Biosciences, Inc.
DATE OF NAME CHANGE: 20151125
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-10-16
0
0001659352
Codiak BioSciences, Inc.
CDAK
0001724575
Flagship Ventures Fund V General Partner LLC
55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE
MA
02142
0
0
1
0
0001627639
Flagship Ventures Fund V, L.P.
55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE
MA
02142
0
0
1
0
0001724939
Flagship V VentureLabs Rx Fund, L.P.
55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE
MA
02142
0
0
1
0
0001222012
AFEYAN NOUBAR
55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE
MA
02142
0
0
1
0
Common Stock
2020-10-16
4
C
0
543686
A
543686
I
See Footnote
Common Stock
2020-10-16
4
C
0
543686
A
543686
I
See Footnote
Common Stock
2020-10-16
4
C
0
338630
A
882316
I
See Footnote
Common Stock
2020-10-16
4
C
0
338630
A
882316
I
See Footnote
Common Stock
2020-10-16
4
C
0
95861
A
978177
I
See Footnote
Common Stock
2020-10-16
4
C
0
95861
A
978177
I
See Footnote
Common Stock
2020-10-16
4
P
0
165000
15.00
A
1143177
I
See Footnote
Common Stock
485949
I
See Footnote
Series A Preferred Stock
2020-10-16
4
C
0
4250000
D
Common Stock
543686
0
I
See Footnote
Series A Preferred Stock
2020-10-16
4
C
0
4250000
D
Common Stock
543686
0
I
See Footnote
Series B Preferred Stock
2020-10-16
4
C
0
2416666
D
Common Stock
338630
0
I
See Footnote
Series B Preferred Stock
2020-10-16
4
C
0
2416666
D
Common Stock
338630
0
I
See Footnote
Series C Preferred Stock
2020-10-16
4
C
0
660048
D
Common Stock
95861
0
I
See Footnote
Series C Preferred Stock
2020-10-16
4
C
0
660048
D
Common Stock
95861
0
I
See Footnote
Each share of Series A Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-7.8170 basis upon the closing of the Issuer's initial public offering on October 16, 2020 and had no expiration date.
Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. serves as the sole manager of Flagship V GP. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Shares held by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx"). Flagship V GP is the general partner of Flagship Fund V Rx. Noubar B. Afeyan, Ph.D. serves as the sole manager of Flagship V GP. Each of the reporting persons except for Flagship Fund V Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Each share of Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-7.1366 basis upon the closing of the Issuer's initial public offering on October 16, 2020 and had no expiration date. The reporting person previously reported shares of common stock into which the Series B Preferred Stock was convertible based on a 1-for-7.1295 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering.
Each share of Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-6.8855 basis upon the closing of the Issuer's initial public offering on October 16, 2020 and had no expiration date. The reporting person previously reported shares of common stock into which the Series C Preferred Stock was convertible based on a 1-for-6.8758 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering.
Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship Fund V is a member of VentureLabs V. Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The general partner of Flagship Fund V is Flagship V GP. Noubar B. Afeyan, Ph.D. serves as the sole director of Flagship Pioneering and as the sole manager of Flagship V GP. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Flagship Ventures Fund V General Partner LLC, By: /s/ Noubar B. Afeyan, Name: Noubar B. Afeyan, Ph.D., Title: Manager
2020-10-20
Flagship Ventures Fund V, L.P., By: Flagship Ventures Fund V General Partner LLC, its general partner, By: /s/ Noubar B. Afeyan, Name: Noubar B. Afeyan, Ph.D., Title: Manager
2020-10-20
Flagship V VentureLabs Rx Fund, L.P., By: Flagship Ventures Fund V General Partner LLC, its general partner, By: /s/ Noubar B. Afeyan, Name: Noubar B. Afeyan, Ph.D., Title: Manager
2020-10-20
/s/ Noubar B. Afeyan, Noubar B. Afeyan, Ph.D.
2020-10-20